Enanta Pharmaceuticals (NASDAQ:ENTA) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from a hold rating to a sell rating in a report released on Saturday morning.

Separately, JMP Securities boosted their price target on shares of Enanta Pharmaceuticals from $23.00 to $24.00 and gave the company a “market outperform” rating in a report on Tuesday, June 3rd. Two investment analysts have rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $18.00.

Enanta Pharmaceuticals Trading Up 1.2%

Enanta Pharmaceuticals stock opened at $7.50 on Friday. Enanta Pharmaceuticals has a 12-month low of $4.09 and a 12-month high of $17.24. The firm has a 50-day moving average price of $5.80 and a 200-day moving average price of $6.13. The firm has a market capitalization of $160.33 million, a PE ratio of -1.52 and a beta of 0.76.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.02). Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. The company had revenue of $14.93 million for the quarter, compared to the consensus estimate of $15.96 million. As a group, sell-side analysts predict that Enanta Pharmaceuticals will post -4.65 earnings per share for the current fiscal year.

Institutional Trading of Enanta Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. US Bancorp DE acquired a new stake in Enanta Pharmaceuticals during the 1st quarter valued at approximately $36,000. GAMMA Investing LLC acquired a new position in shares of Enanta Pharmaceuticals in the 1st quarter valued at $40,000. Tower Research Capital LLC TRC lifted its stake in shares of Enanta Pharmaceuticals by 46.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 2,274 shares during the period. Intech Investment Management LLC acquired a new position in Enanta Pharmaceuticals during the fourth quarter worth $58,000. Finally, Squarepoint Ops LLC acquired a new position in Enanta Pharmaceuticals during the fourth quarter worth $66,000. 94.99% of the stock is currently owned by institutional investors and hedge funds.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.